Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (1063)	2/3/1999 10:09:00 AM
From: John R. Sashko	Read Replies (2) \| Respond to of 2539

FYI on the Celebrex samples. They come in a box with 10 bottles of samples. Each bottle has 50 of the 100 mg dosage. So if the patient is taking 2 per day then it will be 25 days before the RX is actually filled. It is unusual to have such a large number of dosages in an individual sample and this may be impacting the early Celebrex RX numbers. Of course, samples aren't given to all patients and the samples should run out quickly.

To: Anthony Wong who wrote (1063)	2/3/1999 12:37:00 PM
From: Dan Spillane	Read Replies (2) \| Respond to of 2539

Gack! So Monsanto gets 80 percent of the revenue from Celebrex, and yet the houses upgrade PFIZER AND MERCK due to the success of Celebrex?!? Pfizer only gets 20 percent, Merck gets ZERO! What a joke! (from the story) Our revenue estimates for the product are $650 million in 1999 and $900 million in 2000. Pfizer will book its share of profits in its Alliance Revenue line as it does for Lipitor and Aricept currently. We are assuming alliance revenue from Celebrex of $77 million and $113 million for 1999 and 2000, respectively.